Woodline Partners LP disclosed an 8.1% stake in Zevra Therapeutics in an August 14, 2026, regulatory filing. The investment firm holds 4,785,771 shares of common stock. Woodline maintains sole voting and dispositive power over the position.
The disclosure follows a period of significant stock volatility for Zevra. Shares dropped in late July after the European Medicines Agency issued a negative opinion on the company's application for arimoclomol.
Zevra reported strong second-quarter financial results on August 5. Net revenue increased 53% year-over-year. Growth was primarily driven by U.S. sales of the drug MIPLYFFA.